莫西沙星治疗社区获得性肺炎的临床研究

Clinical Study of Moxifloxacin for Treatment of Community Acquired Pneumonia

目的评价莫西沙星单一药物在治疗社区获得性肺炎（CAP）的临床疗效和安全性。方法本研究将2008年2月至2010年6月在我院住院的106例CAP病人分为两组：试验组53例,莫西沙星0.4 g/d;对照组53例,头孢曲松钠2.0 g/d联合阿奇霉素0.5/d,疗程均为7~14 d,观察两组临床疗效和安全性。结果试验组和对照组总有效率分别为90.6%和79.2%,发热消失时间分别为（2.64±1.33）d和（5.39±1.25）d,胸部影像明显吸收（〉50%）时间分别为（7.26±2.41）d和（12.68±2.98）d,细菌清除率分别为87.5%和74.3%,两组比较差异有统计学意义（P〈0.05）;药物不良反应发生率分别为5.66%和7.55%,两组比较差异无统计学意义（P〉0.05）。结论莫西沙星单一用药在治疗CAP病人中疗效更确切,安全性好,值得临床推广应用。

Objective To valuate the clinical effect and safety of Moxifloxacin for treatment of Community Acquired Pneumonia(CAP).MethodsA randomized method was adopted to compare Moxifloxacin 0.4 g/d(test group)with Cefriaxone Soium 2.0 g/d and Azithromycin 0.5/d(control group)for 106 cases of CAP in Hospitalized Patients from Feb 2008 to Jun 2010.After the treatment of 7~14 days,we observed their clinical effect and safety.ResultsCompared with the total efficiency in test group was significantly higher in control group(90.6% vs 79.2%,P<0.05);the time of fever vanishing in test group was significantly shorter than that in control group[(2.64±1.33)d vs(5.39±1.25)d,P<0.05];the ratio of bacteria cleared out in test group was significantly higher that in control group(87.5% vs 74.3%,P<0.05);test group was similar to control group in the ratio of drug side-effect(5.66% vs 7.55%,P>0.05).ConclusionMoxifloxacin has better effect and safety for treatment of CAP,so it may be worth of recommending in clinical experiential use for treatment of CAP.